According to Reuters, the third dose will be available at least six months after the introduction of the second component of the vaccine.

The U.S. Food and Drug Administration (FDA) has authorized the use of a booster dose of the Pfizer – BioNTech consortium vaccine for people aged 16 and 17 years. This was reported on Thursday by Reuters.

According to him, a booster dose can be obtained at least six months after the introduction of the second component of the vaccine. Earlier, the regulator approved the use of a booster dose of the Pfizer – BioNTech vaccine for people aged 18 years and older. According to Reuters, before teenagers can receive a third dose of the vaccine, the U.S. Centers for Disease Control and Prevention (CDC) will probably have to make a similar decision.

On Wednesday, Pfizer and BioNTech issued a statement according to which their vaccine at three doses neutralizes the omicron variant, while at two doses the effectiveness is significantly lower. According to the companies, revaccination can provide sufficient protection against diseases of any severity caused by the Omicron variant.